Search

Publications

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.

Read more

EHA-SWG Scientific Meeting on Aging and Hematology

Dates: October 12-14, 2018
Location: Warsaw, Poland
Chair: D Bron

Organized by:
EHA & the EHA Scientific Working Group on Aging and Hematology

Organizing committee:

D Bron, Institut Jules Bordet, Brussels, Belgium
L Adès, Hopital Saint Louis, Paris, France
R Cordoba, Fundacion Jimenez Diaz University Hospital, Madrid, Spain
T Fulöp, Université…

Read more

EHA-RHS-ROHS Hematology Tutorial on Real World Challenges and Opportunities in Diagnostics and Management of Onco-hematological Patients Today

Dates: April 12-13, 2019
Location: Moscow, Russia
Chairs: P Sonneveld, I Poddubnaya, E Parovichnikova

Goal of the meeting
This 1,5 day meeting focuses on the most vital practical issues in oncohematology to teach the participants the appropriate and effective ways to use all the variety…

Read more

EPICOVIDEHA survey

COVID-19 infections in patients with Hematological Malignancies - Results from EHA-IDWP registry
EPICOVIDEHA is an international open web-based registry for patients with haematological malignancies infected with SARS-CoV-2,
The survey has been approved by the Institutional Review Board and Ethics Committee of the…

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more